Clinical Trial Update: A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis [Phase 1, Phase 2]

View source ↗

Summary

A placebo-controlled study of IV ceftriaxone for refractory psychosis was terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychosis
• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• ceftriaxone (ceftriaxone sodium)

Snippet

Sponsor: Research Foundation for Mental Hygiene, Inc. | Conditions: Psychosis, Schizophrenia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-01-12